Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing ...

Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...

Treatment options for hyperhidrosis have evolved to include well-tolerated therapies with high rates of response.

A pediatric dermatologist calls out cosmetics retailers for aggressive marketing of products that may harm the skin of ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of the novel TYK2 inhibitor ...

Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...